Beta Bionics (Nasdaq:BBNX) shares rose slightly after hours today on fourth-quarter results that topped the consensus forecast. Shares of BBNX ticked up about 1% to $14.10 apiece in post-market trading today. The Irvine, California-based automated insulin delivery system developer reported losses of $13.5 million. That equals 38¢ per share on sales of $32.1 million for […]
Wall Street Beat
Medtronic submits MiniMed Flex to FDA, Diabetes separation is on track amid strong Q4
Medtronic (NYSE:MDT) said today that the separation of its MiniMed Diabetes unit remains on track as it advances the MiniMed Flex system. On the company’s third-quarter earnings call, CFO Thierry Piéton explained the business’ performance as it works toward completing an IPO — for which it filed at the end of 2025 — and bringing […]
Dexcom beats Street in Q4 on 13% sales growth
Dexcom (NSDQ:DXCM) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of DXCM rose 1% to $65.70 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $267.3 million. That equals 68¢ per share on sales of $1.259 billion for […]
Embecta stock ticks up on Street-beating Q1
Embecta (Nasdaq:EMBC) shares got a boost today on first-quarter results that beat the consensus Wall Street forecast. Shares of EMBC rose 6.5% to $12.09 apiece in early-morning trading today. The Parsippany, New Jersey-based BD Diabetes spinoff reported profits of $44.1 million. That equals 74¢ per share on sales of $261.2 million for the three months ended […]
Dexcom stock rises on Street-beating preliminary Q4 sales
Dexcom (NSDQ:DXCM) today announced preliminary fourth-quarter results that included revenues that topped the consensus forecast. For the quarter ended Dec. 31, 2025, the company expects total revenue of $1.26 billion. That marks a 13% increase over the same period a year ago and lands just ahead of expectations on Wall Street. Dexcom expects to report […]
Analysts downgrade Beta Bionics on new patient starts miss
Analysts downgraded Beta Bionics (Nasdaq:BBNX) to “Neutral” following preliminary fourth-quarter results that fell shy of expectations. Shares of BBNX fell 35% to $20.86 apiece in early-morning trading today. Beta Bionics, which has completed its first full year as a public company following its IPO last year, pre-announced fourth-quarter revenues of $32 million. That came in […]
Medtronic Diabetes unit MiniMed files for IPO
Medtronic (NYSE:MDT) announced today that its MiniMed Diabetes business filed with the SEC for a proposed initial public offering (IPO). The medtech giant said MiniMed filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC). It expects to complete the separation from Medtronic through a series of capital markets transactions. […]
Glucose management company LifeScan emerges from Ch. 11
LifeScan announced today that it emerged from its Chapter 11 financial restructuring process as it looks to continue advancing its glucose management offerings. Malvern, Pennsylvania-based LifeScan said in July that it entered into a restructuring support agreement. To implement it, the company filed for Chapter 11. In October, the Chapter 11 bankruptcy reorganization plan received U.S. […]
Medtronic has a new head of investor relations, former head to join Diabetes spin-off MiniMed
![Medtronic named Ingrid Goldberg (right) as its new head of investor relations. Ryan Weispfenning (left) will leave to lead investor relations for MiniMed. [Images from LinkedIn]](https://www.drugdeliverybusiness.com/wp-content/uploads/2025/12/Medtronic-VP-Head-of-investor-relations-Ryan-Weispfenning-MiniMed-Ingrid-Goldberg-150x86.jpg)
Medtronic (NYSE: MDT) announced today that it named Ingrid Goldberg as its new VP and head of investor relations (IR). Goldberg’s appointment comes as Ryan Weispfenning, who previously held that role, elected to join the company’s Diabetes business and lead the IR function for the unit as it continues to work toward a separation from […]
Embecta Q4 sales fall short amid dynamic market, China hurdles
Embecta (Nasdaq:EMBC) today posted fourth-quarter financial results that proved mixed compared to the consensus forecast on Wall Street. Shares of EMBC remained unmoved at $14.64 apiece in pre-market trading today. The Parsippany, New Jersey-based BD Diabetes spinoff reported profits of $26.4 million. That equals 45¢ per share on sales of $264 million for the three […]
